CJC-1295 with DAC is a modified growth hormone-releasing hormone (GHRH) analog designed for extended activity in research settings. The addition of Drug Affinity Complex (DAC) allows for prolonged half-life and sustained signaling, supporting long-acting peptide research models.

This peptide is frequently studied in laboratory environments investigating growth hormone release patterns, IGF-1 signaling, and endocrine system regulation.

Mechanism of Action

CJC-1295 with DAC functions as a GHRH analog, interacting with receptors involved in growth hormone regulation.

Research has explored associations with:

• Increased growth hormone (GH) release • Elevated IGF-1 signaling activity • Support for physiologic, pulsatile hormone release patterns • Extended activity due to albumin-binding properties of DAC

Due to DAC modification, this peptide may require additional time and/or slightly increased solvent volume during reconstitution to achieve full dissolution. Gentle mixing is recommended to ensure complete solubility.

Research Applications

CJC-1295 with DAC is commonly studied in laboratory settings involving:

• Growth hormone and IGF-1 pathway research • Endocrine system signaling studies • Metabolic regulation models • Long-acting peptide and delivery system research

Product Specifications

• Peptide Content: 10mg Lyophilized Peptide • Type: GHRH Analog with DAC • Purity: ≥98% verified by HPLC testing • Form: Lyophilized peptide powder • Storage: Store lyophilized peptide frozen. After reconstitution, maintain refrigerated conditions (2–8°C) and avoid repeated freeze-thaw cycles.

Research Use Notice

This product is intended strictly for laboratory research and analytical purposes only.

• Not for human consumption • Not for veterinary use • Not intended for ingestion, injection, or bodily administration • Not a drug, food, cosmetic, or dietary supplement

All information provided is for educational and scientific reference purposes only.